All In Biotech

Drug Trial Radar · NCT06469164

A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

A Phase I Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmacokinetic Trial of BNT331 Administered in Single Ascending Doses in Healthy Women and Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Jul 1, 2024

Primary completion

Jul 31, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
First posted
Jun 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a two-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy (for Part B) of BNT331 in healthy women (Part A) and in women diagnosed with bacterial vaginosis (BV) (Part B).

Conditions

  • Bacterial Vaginosis

Interventions

  • BNT331Drug

    Vaginal insert

  • PlaceboOther

    Vaginal insert

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAETime frame: Up to 7 days post dose on Day 1
  2. Part B: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Any Serious TEAETime frame: Up to 120 days after first dose on Day 1

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • UAB Sexual Health Research Clinic

    Birmingham, Alabama

  • Praetorian Pharmaceutical Research, LLC

    Marrero, Louisiana

  • Southern Clinical Research Associates - Metairie

    Metairie, Louisiana

  • Women Under Study, LLC

    New Orleans, Louisiana

  • Nucleus Network

    Saint Paul, Minnesota

  • Chattanooga Medical Research, LLC

    Chattanooga, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.